08:04 AM EDT, 05/20/2025 (MT Newswires) -- Atai Life Sciences ( ATAI ) said Tuesday that topline data from a phase 2a trial showed that a single dose of its drug BPL-003, when given to patients who were also taking defined selective serotonin reuptake inhibitors, produced antidepressive effects of up to three months.

The drug was well-tolerated with no serious adverse events, and an average in-clinic treatment time following dosing of less than two hours, the company said.

The 12-patient study showed average MADRS score reductions of 18 to 19 points up to three months post-treatment, supporting prior monotherapy findings, Atai said.

Atai shares were 3.8% lower in recent premarket trading.